{
     "PMID": "16780839",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20061205",
     "LR": "20131121",
     "IS": "0014-4886 (Print) 0014-4886 (Linking)",
     "VI": "201",
     "IP": "2",
     "DP": "2006 Oct",
     "TI": "Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy.",
     "PG": "519-24",
     "AB": "Neurosteroids modulate seizure susceptibility, but their role in the regulation of epileptogenesis is unknown. Status epilepticus (SE) induces temporal lobe epileptogenesis following a latent period in which glial cells are activated. Here, we found that P450scc, the rate-limiting enzyme in steroid synthesis, is upregulated in hippocampal glia during the latent period after pilocarpine-induced SE in rats. More prolonged SE was associated with greater P450scc expression and longer latencies to the development of seizures, suggesting that enhanced steroid synthesis retards epileptogenesis. The 5alpha-reductase inhibitor finasteride, which blocks neurosteroid synthesis, reduced the latent period, indicating that glia-derived neurosteroids may be antiepileptogenic.",
     "FAU": [
          "Biagini, Giuseppe",
          "Baldelli, Enrica",
          "Longo, Daniela",
          "Pradelli, Luca",
          "Zini, Isabella",
          "Rogawski, Michael A",
          "Avoli, Massimo"
     ],
     "AU": [
          "Biagini G",
          "Baldelli E",
          "Longo D",
          "Pradelli L",
          "Zini I",
          "Rogawski MA",
          "Avoli M"
     ],
     "AD": "Dipartimento di Scienze Biomediche, Universita di Modena e Reggio Emilia, Modena, Italy. gbiagini@unimore.it",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20060614",
     "PL": "United States",
     "TA": "Exp Neurol",
     "JT": "Experimental neurology",
     "JID": "0370712",
     "RN": [
          "0 (5-alpha Reductase Inhibitors)",
          "0 (Enzyme Inhibitors)",
          "0 (Steroids)",
          "01MI4Q9DI3 (Pilocarpine)",
          "57GNO57U7G (Finasteride)",
          "EC 1.14.15.6 (Cholesterol Side-Chain Cleavage Enzyme)",
          "EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase)"
     ],
     "SB": "IM",
     "MH": [
          "3-Oxo-5-alpha-Steroid 4-Dehydrogenase/metabolism",
          "5-alpha Reductase Inhibitors",
          "Animals",
          "Cholesterol Side-Chain Cleavage Enzyme/*metabolism",
          "Enzyme Inhibitors/pharmacology",
          "Epilepsy, Temporal Lobe/enzymology/*metabolism",
          "Finasteride/pharmacology",
          "Hippocampus/cytology/enzymology",
          "Immunohistochemistry",
          "Male",
          "Neuroglia/cytology/enzymology",
          "Neurons/enzymology",
          "Pilocarpine",
          "Rats",
          "Rats, Sprague-Dawley",
          "Status Epilepticus/chemically induced/enzymology/*metabolism",
          "Steroids/*metabolism",
          "Time Factors"
     ],
     "EDAT": "2006/06/20 09:00",
     "MHDA": "2006/12/09 09:00",
     "CRDT": [
          "2006/06/20 09:00"
     ],
     "PHST": [
          "2006/01/17 00:00 [received]",
          "2006/03/28 00:00 [revised]",
          "2006/04/21 00:00 [accepted]",
          "2006/06/20 09:00 [pubmed]",
          "2006/12/09 09:00 [medline]",
          "2006/06/20 09:00 [entrez]"
     ],
     "AID": [
          "S0014-4886(06)00271-8 [pii]",
          "10.1016/j.expneurol.2006.04.029 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Exp Neurol. 2006 Oct;201(2):519-24. doi: 10.1016/j.expneurol.2006.04.029. Epub 2006 Jun 14.",
     "term": "hippocampus"
}